News

In a poster presented at MAD-ID 2022, Glenn S. Tillotson, PhD, FIDSA, FCCP, shares data from the Premier Healthcare Database on more than 100,000 patients with C diff.

AdventHealth Orlando studied a small number of these fungal isolates to examine treatment resistance patterns.

At MAD-ID 2022, Payal K. Patel, MD, MPH, FIDSA, discussed how COVID-19 misinformation and lags in diagnostics contributed to inappropriate antibiotic use and offers some way to combat this trend.

In hospitalized COVID-19 patients, remdesivir stewardship reduced hospital length of stay and therapy duration.

Colleen R. Kelly, MD, FACG, speaks at MAD-ID 2022 on alternatives to antibiotics for C diff infection, including the use of probiotics and fecal microbiota transplantation.

The CDC’s COVID-19 booster dose recommendation for children 5 and older comes a few days after the FDA’s authorization

“Clearly, stewardship is a team operation. It starts [with] the leadership, the clinical pharmacy, and coordination with infectious disease physicians truly has to be synergistic,” Goetz said in the keynote address at MAD-ID 2022.

Among community-acquired pneumonia (CAP) outpatients, 49% were prescribed unnecessary antibiotics.

Leveraging antimicrobial stewardship programs was crucial to ensure COVID-19 hospital inpatients received monoclonal antibody therapy quickly and safely.

A review of the neutralizing antibody that was studied in a phase 2/3 trial in outpatients with mild to moderate infections of COVID-19.

The FDA lifted a clinical hold on investigational lenacapavir for HIV treatment and pre-exposure prophylaxis. All clinical studies evaluating injectable lenacapavir can now resume.

Today, the International AIDS Vaccine Initiative (IAVI) and Moderna announced they will soon launch a phase 1 clinical trial for their HIV vaccine candidate, administered with mRNA technology to develop broadly neutralizing antibodies.

A new study in the United Kingdom provided evidence in support of a fourth dose of COVID-19 vaccines, showing a strong boost in immunity.

A third, “booster,” dose of the Pfizer-BioNTech COVID-19 vaccine is now FDA-approved for children 5-11 years old.

As we recently surpassed the 2-year mark of the pandemic, the May issue reflects on lessons learned thus far.

This is the first test authorized for all 3 viruses and is over the counter.

Though it failed to meet its primary study endpoints, post hoc analysis of SNG001 showed the inhalable reduced the risk of severe COVID-19 disease and death in high-risk patients.

Stage 2/3 trials are underway to test the efficacy of J08, a potent monoclonal antibody, to prevent and treat current and future COVID-19 variants.

Tend, a startup company, has developed its Gut Microbiome Collect and Prep (CAP) to enable a standardized method for stool (microbiome) encapsulation for the procedure.

The company is utilizing this platform to address new COVID-19 variants, combination vaccines, and potentially prevent HIV.

COVID-19 patients who do not speak English faced worse hospital outcomes during the first wave of the pandemic.

Tetracycline-class antibiotic, omadacycline (Nuzyra), is FDA approved for community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI), and is also being studied for other potential indications.

A study of pregnant women positive for COVID-19 at delivery found no evidence of vertical transmission, but increased gastrointestinal problems in their newborn infants.

A comparison of COVID-19 PCR tests and rapid self-tests found self-tests to be highly accurate and user-friendly for children.

Phase 3 clinical trial data showed Takeda Pharmaceuticals’ antiviral drug maribavir (Livtencity) was superior to conventional antiviral treatment for clearing cytomegalovirus infections in transplant recipients.

In Part 2 of a video interview, Sornana Segal-Maurer, MD, discusses the newly published research findings that detail the potential of lenacapavir.

The company's investigational vaccine, which is in a phase 3 study, is an example of its commitment to addressing these viruses.